Sai Life Sciences Limited announced its financial results for the first quarter of Fiscal year 2026, with revenue from operations reaching ₹496 Cr, an increase of 77% from the previous year. EBITDA grew by 305% to ₹125 Cr, and the company invested ₹134 Cr in capital expenditure. Business highlights included the inauguration of new facilities to enhance capabilities in complex peptides and emerging modalities. The company’s CEO highlighted the strong performance and commitment to innovation in drug development. The CFO reported a robust performance with revenue up 77% YoY and EBITDA growing 305% YoY, driven by deeper client engagement and investments in infrastructure and capabilities.

Read more at GlobeNewswire: Sai Life Sciences Limited Reports Revenue growth of 77%